A. Russu

发表

Pharmacokinetic-Pharmacodynamic Characterization of Relapse Risk for Paliperidone Palmitate 1-Month and 3-Month Formulations.

M. Mathews, S. Gopal, A. Savitz, 2019, Journal of clinical psychopharmacology.

Bayesian sequential integrationwithin a preclinical PK-PDmodeling framework: Potential challenges and opportunities

C. Faes, H. Geys, J. Serroyen, 2018 .

Modelling of the outcome of non-inferiority trials by integration of historical data

G. De Nicolao, E. V. van Zwet, O. Della Pasqua, 2011, Journal of Pharmacokinetics and Pharmacodynamics.

Tumor-growth inhibition in preclinical animal studies: steady-state analysis of biomarker-driven models

Giuseppe De Nicolao, Italo Poggesi, Maria Luisa Sardu, 2013 .

Evaluating Potential QT Effects of JNJ‐54861911, a BACE Inhibitor in Single‐ and Multiple‐Ascending Dose Studies, and a Thorough QT Trial With Additional Retrospective Confirmation, Using Concentration‐QTc Analysis

Vikash K. Sinha, J. Streffer, L. Tritsmans, 2018, Journal of clinical pharmacology.

Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor

Vikash K. Sinha, E. Liu, L. Shaw, 2016, Alzheimer's & dementia.

Featured Article Profiling the dynamics of CSF and plasma Ab reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor

Vikash K. Sinha, E. Liu, L. Shaw, 2016 .

A PCA approach to population analysis: with application to a Phase II depression trial

G. De Nicolao, R. Gomeni, S. Zamuner, 2013, Journal of Pharmacokinetics and Pharmacodynamics.

Dosing and Switching Strategies for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Based on Population Pharmacokinetic Modeling and Simulation, and Clinical Trial Data

E. Plan, A. Vermeulen, M. Samtani, 2017, CNS Drugs.

Bayesian sequential integration within a preclinical pharmacokinetic and pharmacodynamic modeling framework: Lessons learned

Moreno Ursino, Thomas Jaki, Helena Geys, 2019, Pharmaceutical statistics.

Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study

S. Engelborghs, I. Tesseur, J. Streffer, 2018, Alzheimer's research & therapy.

Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study

S. Engelborghs, G. Novak, I. Tesseur, 2020, Alzheimer's Research & Therapy.

Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab.

E. Liu, Kaori Ito, B. Corrigan, 2016, Journal of Alzheimer's disease : JAD.

Bayesian population approaches to the analysis of dose escalation studies

Giuseppe De Nicolao, Roberto Gomeni, Marta Neve, 2012, Comput. Methods Programs Biomed..

Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia

E. Plan, A. Vermeulen, M. Samtani, 2017, Clinical Pharmacokinetics.

Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab

Kaori Ito, B. Corrigan, H. Brashear, 2015, Alzheimer's & dementia.

Stochastic model search with binary outcomes for genome-wide association studies

Riccardo Bellazzi, Alberto Malovini, Alberto Russu, 2012, J. Am. Medical Informatics Assoc..

Population modelling of patient responses in antidepressant studies: a stochastic approach.

Stefano Zamuner, Roberto Gomeni, Giuseppe De Nicolao, 2015, Mathematical biosciences.

Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trials

Kaori Ito, B. Corrigan, H. Brashear, 2015, Alzheimer's & dementia.

Population model of longitudinal FEV1 data in asthmatics: meta-analysis and predictability of placebo response

G. Nicolao, Shuying Yang, S. Zamuner, 2014, Journal of Pharmacokinetics and Pharmacodynamics.

Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study

Alberto Russu, Sebastiaan Engelborghs, S. Engelborghs, 2018, Alzheimer's Research & Therapy.

Joint Modeling of Efficacy, Dropout, and Tolerability in Flexible‐Dose Trials: A Case Study in Depression

R Gomeni, S Zamuner, A C Hooker, 2012, Clinical pharmacology and therapeutics.

Bayesian Population Modeling of Phase I Dose Escalation Studies: Gaussian Process Versus Parametric Approaches

Giuseppe De Nicolao, Italo Poggesi, Roberto Gomeni, 2011, IEEE Transactions on Biomedical Engineering.

PHARMACODYNAMICS OF THE ORAL BACE INHIBITOR JNJ-54861911 IN EARLY ALZHEIMER'S DISEASE

Vikash K. Sinha, S. Engelborghs, I. Tesseur, 2016, Alzheimer's & Dementia.

Paliperidone Palmitate Long-Acting Injectable Given Intramuscularly in the Deltoid Versus the Gluteal Muscle

S. Gopal, M. Samtani, A. Russu, 2016, Journal of clinical psychopharmacology.

Prospective dose selection and acceleration of paliperidone palmitate 3-month formulation development using a pharmacometric bridging strategy.

S. Gopal, B. Remmerie, A. Savitz, 2016, British journal of clinical pharmacology.